Heterogeneous Klebsiella pneumoniae Co-infections Complicate Personalized Bacteriophage Therapy

Abstract

Multidrug-resistant (MDR) organisms have increased worldwide, posing a major challenge for the clinical management of infection. Bacteriophage is expected as potential effective therapeutic agents for difficult-to-treat infections. When performing bacteriophage therapy, the susceptibility of lytic bacteriophage to the target bacteria is selected by laboratory isolate from patients. The presence of a subpopulation in a main population of tested cells, coupled with the rapid development of phage-resistant populations, will make bacteriophage therapy ineffective. We aimed to treat a man with multifocal urinary tract infections of MDR Klebsiella pneumoniae by phage therapy. However, the presence of polyclonal co-infectious cells in his renal pelvis and bladder led to the failure of three consecutive phage therapies. After analysis, the patient was performed with percutaneous nephrostomy (PCN). A cocktail of bacteriophages was selected for activity against all 21 heterogeneous isolates and irrigated simultaneously via the kidney and bladder to eradicate multifocal colonization, combined with antibiotic treatment. Finally, the patient recovered with an obviously improved bladder. The success of this case provides valuable treatment ideas and solutions for phage treatment of complex infections.Clinical Trial Registrationwww.chictr.org.cn, identifier ChiCTR1900020989.

Phage Selective Pressure Reduces Virulence of Hypervirulent Klebsiella pneumoniae Through Mutation of the wzc Gene

“…In this era of emerging antibiotic resistance, phage therapy, as a personalized treatment, provides a new option for patients who did not respond to antibiotics alone. Although phages have been used clinically (Corbellino et al, 2020;Qin et al, 2020), a detailed understanding of phage biology is required. In this study, two Podoviridae phages, hvKpP1 and hvKpP2, were isolated and characterized.…”

Phage Cocktail Development for Bacteriophage Therapy: Toward Improving Spectrum of Activity Breadth and Depth

“…Of particular interest would be combining both properties into individual, off-the-shelf products, particularly ones targeting multiple strains making up a single bacterial species. These bacterial species could include, for example, Acinetobacter baumannii [71,72], Escherichia coli [73,74], Klebsiella pneumoniae [75], Mycobacterium abscessus [76,77], Pseudomonas aeruginosa [78][79][80][81][82][83][84], or Staphylococcus aureus [3,[85][86][87][88][89][90][91][92][93][94], all of which, as cited, have been treated clinically using phage cocktails.…”

Pre-optimized phage therapy on secondary Acinetobacter baumannii infection in four critical COVID-19 patients

“…Phage particles were purified using CIM® Anion-exchange column QA (BIA Separations, Slovenia) according to the manual. The concentrate was dialysed against 0.9% sodium chloride physiological solution (Shandong Qidu Pharmaceutical) 3 times for a minimum of 3h each [9]. The resulting phage-containing solution was sterilized through a 0.22 µm filter, aliquoted and packaged at the Good Manufacturing Practice (GMP) facility of Zhongshan Hospital of Fudan University, Shanghai, China.…”